News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Industry Trends

>
  • IR Licensing and Partnerships

Latest News

Earned Media and ASCO: Provide Context Beyond the Data
Earned Media and ASCO: Provide Context Beyond the Data
By Michael Christel

May 13th 2025

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
By Don Tracy, Associate Editor

May 13th 2025

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D
Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D
By Don Tracy, Associate Editor

April 28th 2025

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation
Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation
By Don Tracy, Associate Editor

April 22nd 2025

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

Improving Your Earned Media Strategy: Tips and Insights
Improving Your Earned Media Strategy: Tips and Insights
By Michael Christel

April 16th 2025

Introducing a new series highlighting ways pharma companies can up their game in winning earned media—and ultimately deliver greater impact and value from their messaging.

More News


Report: Obesity Drug Market Estimated to be Worth $200 Billion by 2031

Report: Obesity Drug Market Estimated to be Worth $200 Billion by 2031

Don Tracy, Associate Editor
September 11th 2024

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.


Jeremy Goldberg of Arsenal Capital Partners.

Making the Leap from Pharmaceuticals to Private Equity, Venture Capital

Michael Wong
September 11th 2024

A Harvard Business School Healthcare Alumni Association Q&A with Jeremy Goldberg of Arsenal Capital Partners.


How Personal and Digital Engagement Work in Harmony Through the Agile Deployment of Resources

How Personal and Digital Engagement Work in Harmony Through the Agile Deployment of Resources

IQVIA
September 6th 2024

Webinar Date/Time: Thursday, October 3, 2024 at 2pm EDT|11am PDT|7pm BST|8pm CEST


Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

Pharmaceutical Executive Editorial Staff
August 16th 2024

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.


A Promising Option: Exxua

A Promising Option: Exxua

Don Tracy, Associate Editor
August 16th 2024

Surviving a long road, novel next-generation treatment offers hope for major depressive disorder.


Opening the Door: Omvoh

Opening the Door: Omvoh

Mike Hollan
August 16th 2024

Key approval signals progress in addressing immune-mediated inflammatory diseases.


'Marked’ for Stardom?: Truqap

'Marked’ for Stardom?: Truqap

Don Tracy, Associate Editor
August 16th 2024

A breakthrough for biomarker-altered breast cancer—but broader challenges remain.


Branching Off: Wegovy

Branching Off: Wegovy

Mike Hollan
August 16th 2024

New cardiovascular indication builds on treatment’s fast-growing legacy.


A Formidable First: Winrevair

A Formidable First: Winrevair

Miranda Schmalfuhs
August 16th 2024

Launch campaign ramped up for disease-modifying drug that targets rare and fatal form of hypertension.


Morra Aarons-Mele

Reducing Anxiety for Frontline Consultants: Q&A with Morra Aarons-Mele

Michael Wong
August 16th 2024

The author discusses how to calm the nerves of workers during periods of uncertainty.


Michael Abrams

New Pharma vs Big Pharma: Q&A with Michael Abrams

Mike Hollan
August 14th 2024

Abrams discusses how both new pharma and big pharma are reacting to each other and the current market.


Advancing Validation: 2024 Insights and Trends

Advancing Validation: 2024 Insights and Trends

Kneat
August 14th 2024

Webinar Date/Time: Thu, Sep 12, 2024 11:00 AM EDT


Johnson & Johnson MedTech Launches Velys Active Robotic-Assisted System for Planning, Instrumenting Spinal Fusion Procedures

Johnson & Johnson MedTech Launches Velys Active Robotic-Assisted System for Planning, Instrumenting Spinal Fusion Procedures

Don Tracy, Associate Editor
August 5th 2024

Velys recently received 510(k) clearance from the FDA for planning and instrumenting spinal fusion procedures across the cervical, thoracolumbar, and sacroiliac spine.


Gregg Sylvester

Fighting the Drop in Vaccination Rates: Q&A with Gregg Sylvester

Mike Hollan
July 26th 2024

An unexpected consequence of the COVID 19 pandemic has been a loss in trust of vaccines. Over the past three flu seasons, there has been a drop in vaccination rates that is alarming experts. Dr. Gregg Sylvester, chief health officer at CSL Seqirus, spoke with Pharmaceutical Executive about the causes of the decline and how important it is to get the rates back to normal.


Matt Erick

The Future of Biosimilars: Q&A with Matt Erick

Mike Hollan
July 24th 2024

Biocon Biologic’s chief commercial officer of advanced markets discusses the current market and potential trends for biosimilars.


Subin Baral

2024 M&A Recap: Q&A with Subin Baral

Mike Hollan
July 23rd 2024

The deals leader at EY Global Life Sciences discusses how the first half of 2024 fared compared to 2023’s strong ending.


Elevate and De-Risk Your Drug Portfolio Strategy With AI

Elevate and De-Risk Your Drug Portfolio Strategy With AI

Intelligencia
July 18th 2024

Webinar Date/Time: Wed, Aug 28, 2024 11:00 AM EDT


IDN Trends, Insights and Strategies Every Manufacturer Should Know

IDN Trends, Insights and Strategies Every Manufacturer Should Know

Eversana
July 18th 2024

Webinar Date/Time: Thu, Aug 8, 2024 1:00 PM EDT


Dr. Stella Vnook, Founder and President of Oral Biolife

The Future of Periodontal Treatment

Joe Petroziello
July 12th 2024

Advancements in periodontal disease could make way for expansions in the dental space and other medical fields.


Cohort Study Compares Weight Loss Effects of Tirzepatide vs. Semaglutide

Cohort Study Compares Weight Loss Effects of Tirzepatide vs. Semaglutide

Don Tracy, Associate Editor
July 12th 2024

JAMA study aims to discover how weight loss differs between patients receiving tirzepatide compared with semaglutide among a clinical population of overweight of obese adults.


Penn Center for Innovation’s Michael D. Moisel, MS, MBA

What is the Secret Sauce to Convert Academic Ideas to Valued Offerings That Prospective Buyers Crave?

Michael Wong
July 10th 2024

A Harvard Business School Healthcare Alumni Association Q&A with Penn Center for Innovation’s Michael D. Moisel, MS, MBA.


Russell Reynolds’ Global Lead of CEO & Executive Transition Practice, Ty Wiggins, PhD.

With CEO Turnover Rising to Record Levels, How Can Incoming, Existing Executives Build a Sustainable Role?

Michael Wong
June 28th 2024

A Q&A with Russell Reynolds’ Global Lead of CEO & Executive Transition Practice, Ty Wiggins, PhD.


Dan Rizzo

HCP Access Drops but Connected Field Engagement Breaks Through: Q&A with Dan Rizzo

Mike Hollan
June 27th 2024

Veeva’s vice president of global business consulting discusses recent trends in HCP access and how the pharma industry is reacting.


Beyond the Numbers: Extrapolating Today’s Trends Forward

Beyond the Numbers: Extrapolating Today’s Trends Forward

Michael Christel
June 20th 2024

Q&A with Evaluate’s Paul Verdin digs deeper into the data-backed drivers likely to sway the future growth and jockeying of biopharma’s top players.


Kenneth L. Kring is a Senior Client Partner in Korn Ferry's Philadelphia office and co-managing director of the Global Education Practice

How Should Top Business School Deans Change to Lead the Training Grounds of Fortune 500 Future Leaders?

Michael Wong
June 20th 2024

A Q&A with Korn Ferry’s co-managing director of the Global Education Practice, Kenneth L. Kring.


2024 Pharm Exec Top 50 Companies

2024 Pharm Exec Top 50 Companies

Michael Christel
June 14th 2024

Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings such as GLP-1s, Pharm Exec’s latest listing of the top global biopharma sales producers is proof-positive of an industry in transition.


Biopharma Leadership in Times of Transition

Biopharma Leadership in Times of Transition

Michael Christel
June 13th 2024

How pharma and biotech leaders can navigate today’s challenging landscape—focusing on revamped approaches in business operations, talent strategy and development, and more to meet the evolving demands.


The Healthcare System is Changing—So How Should We Respond?

The Healthcare System is Changing—So How Should We Respond?

Jenn Szekely
June 11th 2024

What pharma needs to do to keep up with the rise in value-based care.


Sergio Della Zassa is an executive within Egon Zehnder’s global Health Practice

What Crucial Skill Sets are Global Biopharmas Asking Premier Executive Recruitment Firms to Search for in Top Talent?

Michael Wong
June 11th 2024

A Q&A with Egon Zehnder’s Sergio Della Zassa about what biopharma executives and search firms are looking for in terms of table stakes skill sets and “unicorn” experiences from top talent in the field.


Frances Frei is a Professor at the Harvard Business School

With Layoffs Continuing in 2024 and Employees Paralyzed by Fear for Their Jobs, How Can Leaders Address Crucial Real Problems?

Michael Wong
May 17th 2024

A Q&A with Professor Frances Frei of the Harvard Business School, who discusses how leaders create the conditions for organizations and individuals to thrive by designing for excellence in operations, strategy, and culture.

<12345678
...
19>
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.